Log In
BCIQ
Print this Print this
 

ARV-771

  Manage Alerts
Collapse Summary General Information
Company Arvinas LLC
DescriptionBET bromodomain protein degrader based on Arvinas' proteolysis-targeting chimera (PROTAC) technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer (CRPC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today